Wayne Kuznar


Nivolumab/SBRT Data Leave Role of Radiation Unclear in RCC

February 17th 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma; however, the combination did not meet the primary endpoint of overall response rate.

Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC

February 16th 2020

The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.

Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

February 15th 2020

A neoadjuvant regimen of durvalumab plus olaparib induced a pathologic complete response rate of 50% in patients with muscle-invasive bladder carcinoma.

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

February 14th 2020

Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Cabozantinib Shows Strength After Immunotherapy in Renal Cell Carcinoma

February 10th 2020

Cabozantinib demonstrated impressive progression free survival when administered post-immunotherapy in patients with metastatic renal cell carcinoma.

QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC

January 28th 2020

Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.

Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC

January 27th 2020

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

Second-Line Ramucirumab Improves OS in AFP-Elevated HCC, Regardless of Disease Stage

January 27th 2020

Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.

Triplet and Doublet Regimens Outperform Standard of Care on Survival, QoL in BRAF+ CRC

January 27th 2020

Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.

High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS

January 26th 2020

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.